Understanding genetic factors that affect treatment success in Hodgkin lymphoma
Official title: Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma
Funded at Stanford University · NIH-11047713 · Data updated 2026-11-12
This study is looking at how certain genetic changes and bits of tumor DNA in your blood can help doctors figure out the best treatment for people with classical Hodgkin lymphoma, aiming to create personalized plans that reduce the side effects of chemotherapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | March 4, 2021 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $588,581 |
| NIH project number | 5R01CA257655-05 |
| Project ID | NIH-11047713 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients diagnosed with classical Hodgkin lymphoma who are undergoing treatment.
✕Less likely to help
Patients with other types of lymphoma or those who are not currently receiving treatment for Hodgkin lymphoma may not benefit from this research.
What this research studies
This research investigates how genetic mutations and circulating tumor DNA can help predict treatment outcomes for patients with classical Hodgkin lymphoma. By analyzing both baseline and dynamic risk factors, including imaging studies, the researchers aim to develop personalized treatment strategies that minimize the long-term side effects of chemotherapy. The study employs advanced techniques to noninvasively assess the genomic landscape of Hodgkin lymphoma, which could lead to improved prognostication and tailored therapies for patients.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for Hodgkin lymphoma patients, reducing the risk of treatment failure and long-term side effects.
How similar studies have gone: Previous research has shown promise in using genetic and molecular markers to predict treatment outcomes in various cancers, suggesting that this approach could be effective for Hodgkin lymphoma as well.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Alizadeh, Ash Arash — Stanford University
- Study coordinator: Alizadeh, Ash Arash
Related research
Other NIH-funded projects on the same topics.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Trajectories of Neurotoxicity in young Hodgkin lymphoma patients
Aging Hodgkin lymphoma patients who are adolescents or young adults may face long-lasting brain and nerve-related side effects from their cancer treatment, and this study aims to map how those problems develop over time.
-
Combination therapy approach for non-Hodgkin lymphoma (NHL)
A Mayo Clinic team is testing a new combination treatment for non-Hodgkin lymphoma to improve responses in patients and in dogs with similar disease.
-
Multi-antigen T cell therapy for relapsed NHL
A patient-derived T cell therapy called MT-601 targets six tumor-associated antigens to help treat relapsed non-Hodgkin lymphoma after other therapies may have failed.
-
Personalized de‑intensification of therapy for NLP Hodgkin lymphoma
A clinician-scientist at Stanford is developing a patient-centered program to tailor and reduce therapy for nodular lymphocyte-predominant Hodgkin lymphoma using tumor and blood samples.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.